Diffuse large B-cell lymphoma (DLBCL) is the most common type of non-Hodgkin lymphoma. It is an aggressive cancer that develops from B lymphocytes, a type of white blood cell that plays an important role in the immune system. Although DLBCL can grow rapidly, it is often treatable, and many patients achieve long-term remission with modern therapies. Early diagnosis and prompt treatment are key factors in improving outcomes. Early diagnosis, individualized treatment planning, and regular follow-up with a hematology and oncology team are essential for achieving the best possible long-term results.
DLBCL begins when abnormal B cells multiply uncontrollably, usually within the lymph nodes, but it can also develop in organs such as the stomach, intestines, skin, brain, or bone.
Because it is considered an aggressive lymphoma, treatment typically begins soon after diagnosis.
Symptoms vary depending on where the lymphoma develops and may include:
Some people experience "B symptoms," which include fever, drenching night sweats, and significant unexplained weight loss.
Factors associated with an increased risk of DLBCL include:
Many individuals diagnosed with DLBCL have no identifiable risk factors.
Diagnosis typically involves several tests to confirm the disease and determine its stage.
Common tests include:
These evaluations help guide treatment decisions.
Treatment depends on the stage of the disease, overall health, and specific characteristics of the lymphoma.
Possible treatments include:
Many patients receive a combination of therapies.
Regular monitoring helps assess treatment response and detect side effects.
Follow-up may include:
Results help determine whether additional treatment is needed.
After completing therapy, long-term follow-up is important to monitor recovery and overall health.
Healthcare providers may recommend:
Follow-up schedules vary depending on individual circumstances.
Prompt medical evaluation is recommended if symptoms include:
Early evaluation can help identify complications or disease progression.
Diffuse large B-cell lymphoma is an aggressive but often treatable form of non-Hodgkin lymphoma. Advances in chemotherapy, immunotherapy, targeted therapy, and cellular therapies have improved outcomes for many patients.